Navigation Links
Chiltern Announces The Promotion Of Alecia Barbee To VP, Global Biometrics
Date:5/29/2013

LONDON and WILMINGTON, N.C., May 30, 2013 /PRNewswire/ -- Chiltern International Limited (Chiltern), a global contract research organization (CRO), announces the promotion of Alecia Barbee to the position of Vice President, Global Biometrics.

Dr Jim Esinhart , CEO of Chiltern stated: "We are extremely pleased to announce the promotion of Alecia Barbee from Executive Director of Biometrics to VP of Global Biometrics. In this role, Alecia will have global oversight of data management, data programming, biostatistics and e-clinical functions in Chiltern to provide the best-in-class and comprehensive biometrics solutions to our global client base." 

Alecia Barbee has more than 20 years of CRO experience and joined Chiltern in 2006. Prior to her promotion, Alecia was responsible for oversight of all Biometrics activities in the US.  Alecia is a member of the Drug Information Association and the Society for Clinical Data Management. Alecia is based in Wilmington, NC.

Aize Smink, Chief Operating Officer of Chiltern added: "With Alecia's long, highly successful track record within Chiltern and previously with other major CROs, I am proud to have Alecia represent Biometrics on our global operations management team. With her dedication and hands on approach, we will continue to differentiate Chiltern as a solid mid-sized alternative for our clients who prefer a more tailored approach to their strategic objectives."

Chiltern's innovative approach on more than 200 Electronic Data Capture (EDC) studies in the last 5 years is continually exceeding our sponsors' expectations. The depth of our expertise gives Chiltern the ability to customize and deliver on the particular needs of our clients. We have also expanded our experience in Clinical Data Interchange Standards Consortium (CDISC) standards and provide our sponsors with fully compliant submission ready Study Data Tabulation Model (SDTM) and Analysis Data Model (ADaM) deliverables.

Company profileAbout Chiltern:
Established in 1982, Chiltern is a leading global clinical CRO with extensive experience in the management of Phase I-IV clinical trials across a broad range of therapeutic areas, functional service provision and contract staffing solutions. Chiltern has conducted trials in more than 40 countries, employs more than 1,500 people globally and offers services in Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions. Chiltern prides itself as a development partner that offers flexibility, responsiveness and quality delivery. Further information is available at: www.chiltern.com. For more information contact:Natalie Chong

Susan OjanenMarketing Director

Marketing ExecutiveChiltern International Ltd.

Chiltern International Inc.171 Bath Road

1241 Volunteer ParkwaySlough

Suite 950Berkshire SL1 4AA

Bristol, TN 37620UNITED KINGDOM

USATel:  +44 (0) 1753 512 000

Tel:  +1 (423) 968 9533Fax: +44 (0) 1753 511 116

Fax: +1 (423) 968 3567Email: natalie.chong@chiltern.com

Email: susan.ojanen@chiltern.com


'/>"/>
SOURCE Chiltern
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. Chiltern Wins CRO Leadership Award From Life Science Leader
2. Chiltern Welcomes Cedric Burg And James Gunter
3. Modern Mobility Aids, Inc. Announces a Revised Agreement for the Acquisition of Lumigene
4. ChromaDex® Announces Financial Results for the Year Ended 2011
5. Improved Authentication and Confidentiality Protection. ICAP Patent Brokerage Announces for Auction Important Patents in Data Encryption and Document Security
6. FirstMark Announces New Hire Jay Houtman as Southeast Regional Sales Manager
7. Global Information Inc. Announces Discounted Conference Registration For Bio-IT World Asia and Biodetection Technologies 2012
8. Virginia Tech announces 2012 football helmet ratings; 2 more added to the 5-star mark
9. Medbox, Inc. Announces Top-Tier Rating by Dun & Bradstreet Credibility Corporation
10. BioLife Solutions Announces 7th Consecutive Quarter of Record Revenue
11. Mass. Eye and Ear announces Curing Kids Fund grant recipients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2016)...  The American College of Medical Genetics and Genomics was ... as one of the fastest-growing trade shows during the Fastest ... in Las Vegas . ... in each of the following categories: net square feet of ... attendees. The 2015 ACMG Annual Meeting was ranked 23 out ...
(Date:6/22/2016)... WASHINGTON , June 22, 2016 On ... highly-anticipated call to industry to share solutions for the ... by U.S. Customs and Border Protection (CBP), explains that ... nationals are departing the United States ... criminals, and to defeat imposters. Logo - ...
(Date:6/20/2016)... 2016 Securus Technologies, a leading provider ... public safety, investigation, corrections and monitoring announced that ... has secured the final acceptance by all three ... Access Systems (MAS) installed. Furthermore, Securus will have ... installed by October, 2016. MAS distinguishes between legitimate ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ON , June 27, 2016 /PRNewswire/ - BIOREM Inc. ... has been advised by its major shareholders, Clean Technology ... United States based venture capital ... shares of Biorem (on a fully diluted, as converted ... the disposition of their entire equity holdings in Biorem ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... Amgen, will join the faculty of the University of North Carolina Kenan-Flagler ... of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers ... 5000 and the 6000i models are higher end machines that use the more unconventional ... spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci has ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
Breaking Biology Technology: